MedTrace Logo

Appetite Suppression / Hormone Study Control Group

NCT02029677 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2024-05-31

No results posted yet for this study

Summary

The purpose of this research study is to determine how changes in levels of obesity-related hormones in the gastrointestinal tract following Laparoscopic Adjustable Gastric Banding (LAGB) surgery may lead to a decrease in appetite and weight loss. Learning exactly how the Lap Band works may help us to develop new, less invasive treatments for morbid obesity. This knowledge may also lead to the development of preventive, cost-effective treatment strategies. As a control subject, participants will provide a comparison for changes in these hormones with medical weight loss compared to weight loss after LAGB surgery.

Conditions

  • Morbid Obesity
  • Bariatric Surgery Patient

Sponsors & Collaborators

  • Legacy Health System

    collaborator OTHER

  • Allergan

    collaborator INDUSTRY

  • Oregon Weight Loss Surgery, LLC

    lead OTHER

Principal Investigators

  • Emma J Patterson, MD · Oregon Weight Loss Surgery

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02029677 on ClinicalTrials.gov